[go: up one dir, main page]

MA43978A - Dérivé de sulfonamide hétérocyclique et médicament le contenant - Google Patents

Dérivé de sulfonamide hétérocyclique et médicament le contenant

Info

Publication number
MA43978A
MA43978A MA043978A MA43978A MA43978A MA 43978 A MA43978 A MA 43978A MA 043978 A MA043978 A MA 043978A MA 43978 A MA43978 A MA 43978A MA 43978 A MA43978 A MA 43978A
Authority
MA
Morocco
Prior art keywords
product containing
medicinal product
sulfonamide derivative
heterocyclic sulfonamide
heterocyclic
Prior art date
Application number
MA043978A
Other languages
English (en)
Inventor
Kaori Kobayashi
Tatsuya Okuzumi
Tamotsu Suzuki
Original Assignee
Ea Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ea Pharma Co Ltd filed Critical Ea Pharma Co Ltd
Publication of MA43978A publication Critical patent/MA43978A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MA043978A 2016-02-05 2017-02-03 Dérivé de sulfonamide hétérocyclique et médicament le contenant MA43978A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016021358 2016-02-05

Publications (1)

Publication Number Publication Date
MA43978A true MA43978A (fr) 2018-12-12

Family

ID=59499709

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043978A MA43978A (fr) 2016-02-05 2017-02-03 Dérivé de sulfonamide hétérocyclique et médicament le contenant

Country Status (14)

Country Link
US (1) US10584116B2 (fr)
EP (1) EP3412664B1 (fr)
JP (1) JP6906449B2 (fr)
KR (1) KR102766396B1 (fr)
CN (1) CN108602807B (fr)
AU (1) AU2017213993B2 (fr)
CA (1) CA3012812A1 (fr)
DK (1) DK3412664T3 (fr)
EA (1) EA037264B1 (fr)
ES (1) ES2911416T3 (fr)
MA (1) MA43978A (fr)
MX (1) MX2018009458A (fr)
PL (1) PL3412664T3 (fr)
WO (1) WO2017135462A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3487853B1 (fr) * 2016-07-20 2022-06-08 F. Hoffmann-La Roche AG Composés de proline bicycliques
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
WO2023033097A1 (fr) * 2021-09-02 2023-03-09 Eaファーマ株式会社 Procédé de production d'un dérivé de sulfonamide hétérocyclique et intermédiaire synthétique de celui-ci
WO2024099403A1 (fr) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Composé thioéther ayant une propriété de médicament doux et son utilisation, composition pharmaceutique et utilisation associées

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
WO2010141805A1 (fr) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Amides hétérocycliques en tant que modulateurs de la trpa1
EP2520566A1 (fr) * 2011-05-06 2012-11-07 Orion Corporation Nouveaux composés pharmaceutiques
WO2013108857A1 (fr) 2012-01-17 2013-07-25 味の素株式会社 Dérivé d'amine hétérocyclique et produit pharmaceutique le contenant
TW201418201A (zh) 2012-09-27 2014-05-16 Hoffmann La Roche 經取代之磺醯胺化合物
JP6301842B2 (ja) * 2012-12-18 2018-03-28 Eaファーマ株式会社 複素環アミド誘導体及びそれを含有する医薬
EP2774919A1 (fr) 2013-03-06 2014-09-10 Pharmeste S.R.L. In Liquidazione Nouveaux antagonistes des récepteurs TRPA1 de sulfonamide
HUE041652T2 (hu) * 2013-10-11 2019-05-28 Hoffmann La Roche TRPA1-modulátorokként hasznos szubsztituált heterociklusos szulfonamid-vegyületek
WO2015115507A1 (fr) 2014-01-28 2015-08-06 味の素株式会社 Dérivé de sulfonamide hétérocyclique et médicament le contenant
PT3256463T (pt) 2015-02-15 2019-12-05 Hoffmann La Roche Derivados de 1-(het)arilsulfonil-(pirrolidina ou piperidina)-2-carboxamida e a sua utilização como antagonistas do trpa1
EP3330266A1 (fr) 2015-07-29 2018-06-06 Ea Pharma Co., Ltd. Dérivé cyclopropane et médicament le contenant

Also Published As

Publication number Publication date
AU2017213993A1 (en) 2018-09-13
KR20180104150A (ko) 2018-09-19
CN108602807A (zh) 2018-09-28
ES2911416T3 (es) 2022-05-19
EA037264B1 (ru) 2021-03-01
PL3412664T3 (pl) 2022-06-06
EP3412664A1 (fr) 2018-12-12
MX2018009458A (es) 2018-09-21
EP3412664B1 (fr) 2022-03-30
WO2017135462A1 (fr) 2017-08-10
KR102766396B1 (ko) 2025-02-13
US10584116B2 (en) 2020-03-10
AU2017213993B2 (en) 2021-03-25
JPWO2017135462A1 (ja) 2018-12-13
CA3012812A1 (fr) 2017-08-10
EP3412664A4 (fr) 2019-10-16
EA201891782A1 (ru) 2019-06-28
DK3412664T3 (da) 2022-06-07
BR112018015851A2 (pt) 2018-12-26
CN108602807B (zh) 2022-05-13
JP6906449B2 (ja) 2021-07-21
US20190023699A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
HUE058677T2 (hu) Meloxicamot tartalmazó gyógyászati készítmény
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
EP4209238C0 (fr) Nébuliseur et cartouche
DK3532029T3 (da) Flydende farmaceutisk sammensætning
EP3424940A4 (fr) Médicament radiomarqué
EP3101015A4 (fr) Dérivé de sulfonamide hétérocyclique et médicament le contenant
EP3351533A4 (fr) Dérivé biaryle et médicament le contenant
MA43705A (fr) Formulation pharmaceutique
MA43978A (fr) Dérivé de sulfonamide hétérocyclique et médicament le contenant
CL2019000563S1 (es) Envase y dispendio de medicamentos. (divisional solicitud 201800718)
EP3437644A4 (fr) Médicament
MA44987A (fr) Formulations de médicaments améliorées
EP3727531C0 (fr) Nébuliseur et cartouche
EP3609802A4 (fr) Récipient cassable
DK3426681T3 (da) Åbne hla-b57-konformere
EP3383397A4 (fr) Compositions pharmaceutiques contenant de la doravirine, du fumarate de ténofovir disoproxil et de la lamivudine
EP3434681A4 (fr) Complexe de curcumine-bore et agent pharmaceutique le contenant
MA45457A (fr) Médicament ophtalmique contenant du salbutamol.
EP3527216A4 (fr) Médicament
EP3623384A4 (fr) Anticorps anti-cldn-5, et médicament le contenant
LT3601277T (lt) Farmacinė vaisto forma
DK3432887T3 (da) Anti-tuberkulosemiddel
EP3434251A4 (fr) Récipient pour médicament
DK3453390T3 (da) Farmaceutisk sammensætning indeholdende polymeriseret lægemiddel
MA46642A (fr) Promédicaments d'inhibiteurs de la kallicréine